Literature DB >> 9755716

Bioreductive drugs into the next millennium.

I J Stratford1, P Workman.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1998        PMID： 9755716

Source DB:  PubMed          Journal:  Anticancer Drug Des        ISSN： 0266-9536


× No keyword cloud information.
  8 in total

Review 1.  Employing tumor hypoxia for oncolytic therapy in breast cancer.

Authors:  Yun Shin Chun; Prasad S Adusumilli; Yuman Fong
Journal:  J Mammary Gland Biol Neoplasia       Date:  2005-10       Impact factor: 2.673

Review 2.  EO9 (Apaziquone): from the clinic to the laboratory and back again.

Authors:  Roger M Phillips; Hans R Hendriks; Godefridus J Peters
Journal:  Br J Pharmacol       Date:  2013-01       Impact factor: 8.739

3.  The hypoxia-selective cytotoxin NLCQ-1 (NSC 709257) controls metastatic disease when used as an adjuvant to radiotherapy.

Authors:  S J Lunt; C Cawthorne; M Ali; B A Telfer; M Babur; A Smigova; P J Julyan; P M Price; I J Stratford; W D Bloomer; M V Papadopoulou; K J Williams
Journal:  Br J Cancer       Date:  2010-06-29       Impact factor: 7.640

4.  Enhancement of chemotherapy and radiotherapy of murine tumours by AQ4N, a bioreductively activated anti-tumour agent.

Authors:  L H Patterson; S R McKeown; K Ruparelia; J A Double; M C Bibby; S Cole; I J Stratford
Journal:  Br J Cancer       Date:  2000-06       Impact factor: 7.640

Review 5.  Design of optimized hypoxia-activated prodrugs using pharmacokinetic/pharmacodynamic modeling.

Authors:  Annika Foehrenbacher; Timothy W Secomb; William R Wilson; Kevin O Hicks
Journal:  Front Oncol       Date:  2013-12-27       Impact factor: 6.244

6.  In vivo evaluation of [18F]fluoroetanidazole as a new marker for imaging tumour hypoxia with positron emission tomography.

Authors:  H Barthel; H Wilson; D R Collingridge; G Brown; S Osman; S K Luthra; F Brady; P Workman; P M Price; E O Aboagye
Journal:  Br J Cancer       Date:  2004-06-01       Impact factor: 7.640

7.  Professor Tom Connors and the development of novel cancer therapies by the Phase I/II Clinical Trials Committee of Cancer Research UK.

Authors:  D R Newell; K M Searle; N B Westwood; S S Burtles
Journal:  Br J Cancer       Date:  2003-08-04       Impact factor: 7.640

Review 8.  Bioreductive prodrugs as cancer therapeutics: targeting tumor hypoxia.

Authors:  Christopher P Guise; Alexandra M Mowday; Amir Ashoorzadeh; Ran Yuan; Wan-Hua Lin; Dong-Hai Wu; Jeff B Smaill; Adam V Patterson; Ke Ding
Journal:  Chin J Cancer       Date:  2013-07-12
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.